BEGIN:VCALENDAR
PRODID:-//Columba Systems Ltd//NONSGML CPNG/SpringViewer/ICal Output/3.3-
 M3//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTAMP:20180413T140351Z
DTSTART:20180425T113000Z
DTEND:20180425T153000Z
SUMMARY:The Search for New Treatments for Psychosis
UID:{http://www.columbasystems.com/customers/uom/gpp/eventid/}flp-jfy0kqx
 3-ww4b2i
DESCRIPTION:A DNEP Translational Workshop with Distinguished Visiting Lec
 turer\, Alan J Cross and interactive panel presentations and discussion.
 \nAlan Cross will present the DNEP visiting lecture from 12:30-1:30. He 
 will survey the current state of the art from his long experience of dru
 g discovery in academia and industry. \nThe Workshop will have 6 expert 
 panellists to discuss the way forward with Alan. We’ll discuss the appro
 aches - cognitive and molecular subtyping\, rodent – human translation\,
  drug repurposing\, stem cell models\, the role of inflammation. Bring y
 our ideas too.    \n\nAlan J Cross: The Search for New Treatments for Ps
 ychosis\n"Despite 50 years of neuropharmacological research\, efforts to
  discover new treatments for schizophrenia beyond D2 receptor antagonist
 -based approaches have failed. Genetics/genomics promises to reveal new 
 potential drug targets\, although the path to new treatments is unclear 
 and beyond the scope of current efforts. Translational approaches are ke
 y to future success: i) genes to targets\; ii) drug candidates to proof 
 of concept"\n\nBioSketch\nTrained at Department of Biochemistry\, Univer
 sity of Sheffield and Institute of Psychiatry\, University of London UK\
 , conducted postdoctoral studies at the Division of Psychiatry\, MRC Cli
 nical Research Centre\, Harrow\, and then became Lecturer in Neurochemis
 try & Physiology\, University of Manchester\, UK. \nJoined Astra in 1986
  and held positions as Senior Scientist and Head of Pharmacology at the 
 Astra Neuroscience Research Unit in London UK\, and was Project Director
  for several projects in neurodegeneration and Alzheimers Disease. In 19
 96 moved to Astra USA\, Rochester NY\, and then to AstraZeneca Wilmingto
 n as Director of Neuroscience and Disease Area Leader\, Psychiatry worki
 ng across the interface between Discovery\, Development and Commercial o
 rganizations to formulate and update the Disease Area Strategy. Interim 
 Site Head at AstraZeneca CNS Discovery Wilmington\, responsible for >250
  personnel. \nAppointed Chief Scientist in 2010\, and joined the AstraZe
 neca Neuroscience Innovative Medicines Unit in Cambridge\, MA in 2012 un
 til 2016.\nCurrently acts as an advisor to the National Institute of Men
 tal Health\, Lieber Institute of Brain Development and AstraZeneca Neuro
 science and is Chief Scientific Officer at Cylenta Pharmaceuticals.\nLea
 ds and is involved in a range of collaborations with government\, academ
 ic\, biotech and privately funded organizations\, ranging from genomics 
 and iPS cell modeling to early clinical development and Phase 2 PoC stud
 ies. Over 200 publications in the area of neuropharmacology\, neurodegen
 eration and neuropsychiatric disorders and inventor on 4 patents.\n\n\nR
 egister via Eventbrite: https://www.eventbrite.com/e/dnep-translational-
 lecture-and-workshop-tickets-44833005727 \n\nProgram\n\n12:00 Lunch fing
 er buffet "Food for Thought" café\, Zochonis Building\n\n12:30 - 1:30	\n
 DNEP Distinguished Visitor Lecture Alan Cross: \nThe search for new trea
 tments for psychosis\n\n1:30 - 3:00	Workshop session 1\nFinding new trea
 tments for schizophrenia \nMolecular mechanisms\, biomarkers\, subtyping
  and treatments\nChair: Alison Yung\n\n1:30	\nNeil Hanley (Developmental
  Medicine) New genes and target mechanisms from human neurodevelopment\n
 \n1:50 	\nBill Deakin (DNEP) Dopamine\, glutamate and GABA function and 
 clinical subtypes \n\n2:10 \nPeter Talbot (DNEP) Inflammation and psycho
 sis\; implications for treatment\n\n2:30 General discussion with Panel \
 n\n2:40 - 3:00	Tea Coffee\n\n3:00 - 4:30	Workshop session 2\nNeural syst
 ems\; targets\, biomarkers\, subtyping and treatments\nChair: Shon Lewis
 \n\n3:00 \nRebecca Elliott (DNEP) Social\, emotional and motivational co
 gnitive processes – potential surrogates for efficacy?\n3:20 \nJo Neill 
 (Pharmacy) Modelling cognition and aspects of negative symptoms from rod
 ents to humans\n\n4:00 \nBrief ideas session\nBo Yao: Modelling and meas
 uring hallucinations in psychosis\nOthers: EEG\, MEG\, Primary cortical 
 dysfunction……?\n\n4:15 	\nFinding new treatments for psychosis: concludi
 ng discussion \nAllan Cross and Panel  \n\n4:30 Close\n
STATUS:TENTATIVE
TRANSP:TRANSPARENT
CLASS:PUBLIC
LOCATION:Lecture Theatre A\, Zochonis Building\, Manchester
END:VEVENT
END:VCALENDAR